Cellectis S.A. (CLLS) — Analyst outlook / Analyst consensus target is. Based on 16 analyst ratings, the consensus is bullish — 13 Buy, 2 Hold, 1 Sell.
The consensus price target is $6.00 (low: $4.00, high: $8.00), representing an upside of 46.7% from the current price $4.09.
Analysts estimate Earnings Per Share (EPS) of $-0.63 and revenue of $0.04B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-0.37 vs est $-0.63 (beat +41.5%). 2025: actual $-0.68 vs est $-0.76 (beat +10.2%). Analyst accuracy: 59%.
CLLS Stock — 12-Month Price Forecast
$6.00
▲ +46.70% Upside
Average Price Target
Based on 16 Wall Street analysts offering 12-month price targets for Cellectis S.A., the average price target is $6.00, with a high forecast of $8.00, and a low forecast of $4.00.
The average price target represents a +46.70% change from the last price of $4.09.
Highest Price Target
$8.00
Average Price Target
$6.00
Lowest Price Target
$4.00
CLLS Analyst Ratings
Buy
Based on 16 analysts giving stock ratings to Cellectis S.A. in the past 3 months
EPS Estimates — CLLS
59%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$0.37
vs Est –$0.63
▲ 71.1% off
2025
Actual –$0.68
vs Est –$0.76
▲ 11.3% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — CLLS
97%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.042B
vs Est $0.042B
▼ 0.0% off
2025
Actual $0.073B
vs Est $0.077B
▼ 5.7% off
Revenue Trend
Strong revenue growth over the period shown. Analysts forecast revenue contraction ahead.
